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ABSTRACT
Objectives: To examine trends in opioid prescribing
in primary care, identify patient and general practice
characteristics associated with long-term and stronger
opioid prescribing, and identify associations with
changes in opioid prescribing.
Design: Trend, cross-sectional and longitudinal
analyses of routinely recorded patient data.
Setting: 111 primary care practices in Leeds and
Bradford, UK.
Participants: We observed 471 828 patient-years in
which all patients represented had at least 1 opioid
prescription between April 2005 and March 2012. A
cross-sectional analysis included 99 847 patients
prescribed opioids between April 2011 and March 2012.
A longitudinal analysis included 49 065 patient-years
between April 2008 and March 2012. We excluded
patients with cancer or treated for substance misuse.
Main outcome measures: Long-term opioid
prescribing (4 or more prescriptions within 12 months),
stronger opioid prescribing and stepping up to or down
from stronger opioids.
Results: Opioid prescribing in the adult population
almost doubled for weaker opioids over 2005–2012 and
rose over sixfold for stronger opioids. There was marked
variation among general practices in the odds of patients
stepping up to stronger opioids compared with those not
stepping up (range 0.31–3.36), unexplained by practice-
level variables. Stepping up to stronger opioids was most
strongly associated with being underweight (adjusted OR
3.26, 1.49 to 7.17), increasing polypharmacy (4.15, 3.26
to 5.29 for 10 or more repeat prescriptions), increasing
numbers of primary care appointments (3.04, 2.48 to
3.73 for over 12 appointments in the year) and referrals
to specialist pain services (5.17, 4.37 to 6.12). Compared
with women under 50 years, men under 50 were less
likely to step down once prescribed stronger opioids
(0.53, 0.37 to 0.75).
Conclusions:While clinicians should be alert to
patients at risk of escalated opioid prescribing, much
prescribing variation may be attributable to clinical
behaviour. Effective strategies targeting clinicians and
patients are needed to curb rising prescribing, especially
of stronger opioids.
BACKGROUND
There is international concern over rising
trends in opioid prescribing,1–9 largely attribu-
ted to prescribing for chronic non-cancer
pain.10 Despite known short-term efﬁcacy of
opioids in neuropathic and musculoskeletal
pain, evidence is limited on longer term effects
on pain, quality of life, functioning, tolerance
and addiction.11–14 The degree of pain relief
obtained for chronic pain is often of marginal
clinical importance.15 Efﬁcacy decreases with
long-term opioid use, although dependence
can make treatment withdrawal challenging.16
Prescribed opioids are associated with psycho-
social problems, hospitalisation and, even for
weaker opioids such as codeine, increased mor-
tality.17–20 The ‘opioid epidemic’ in the USA
has coincided with sharp increases in prescrip-
tion opioid-related deaths and overdoses.21
There is concern that patients with chronic
pain are inappropriately being moved up the
WHO ‘analgesic ladder’, originally devel-
oped for cancer pain, without considering
alternatives to medication.22–24 Over a third
of one patient cohort eventually more than
Strengths and limitations of this study
▪ Novel use of routine data to identify patient-level
and practice-level characteristics associated with
individual opioid prescribing trajectories.
▪ Findings based on a large sample of primary
care practices and patients from diverse metro-
politan populations.
▪ Identified associations cannot be assumed as
casual.
▪ Exploratory work involving multiple statistical
testing will have increased risk of type 1 errors
and hence falsely positive associations.
▪ Detection and magnitude of associations will
have been affected by imprecision and biases
inherent in routinely recorded data.
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doubled their original dose of opioids while around
10% were prescribed potentially hazardous high doses.23
Previous research has identiﬁed patient characteristics
associated with long-term opioid prescribing, which
include female gender; increasing age; comorbidities;
mental health disorders; and prescribed benzodiaze-
pines, anticonvulsants or antidepressants.2 23 25–29
Strong or higher dose long-term opioid prescribing is
associated with female gender, middle age, socio-
economic deprivation, care home residence, mood dis-
orders, neuropathy, low back pain, polypharmacy, prior
prescribing of weak opioids and nicotine depend-
ence.9 23 30 31 Initiation of opioid prescribing is asso-
ciated with higher baseline levels of pain, psychological
distress, substance misuse and unhealthy lifestyles.2 32–37
However, most of these studies took place in selected
patient groups, for example, trial participants or military
veterans;34 37 less is known about factors associated with
such trajectories in typical primary care populations.
Long-term prescribing may follow hospitalisation but
usually starts in primary care.29 There are well-
documented variations in wider prescribing practice and
safety in UK general practice.38 Structural factors such as
practice list size and postgraduate general practitioner
(GP) training status only marginally explain variations in
high-risk prescribing (potentially inappropriate prescrib-
ing of drugs to patients vulnerable to adverse drug
events)39 and none in strong opioid prescribing.9
We aimed to improve understanding of patient trajec-
tories towards long-term and stronger opioid prescribing
in a UK primary care population. We examined trends
and analysed routinely recorded primary care popula-
tion data to identify patient and general practice
characteristics associated with long-term prescribing,
stronger opioid prescribing, and stepping up or down
between weaker and stronger opioids.
METHODS
Study design and setting
First, we examined trends in opioid prescribing between
1 April 2005 and 31 March 2012 using routinely collected
data from general practices in Leeds and Bradford, UK.
Second, we conducted a cross-sectional analysis to iden-
tify patient and practice characteristics associated with
long-term and stronger opioid prescribing (April 2011 to
March 2012). Third, we undertook a longitudinal analysis
to examine associations with stepping up to or down
from stronger opioids (April 2008 to March 2012). Leeds
and Bradford have a combined population of almost 1.3
million. Leeds is typical of UK cities in terms of social
deprivation indices and demographics. Bradford is more
socially deprived and ethnically diverse; one-ﬁfth of the
population is of Pakistani ethnic origin.40
Study participants
There were 192 general practices in Leeds and Bradford
in May 2012. We invited all 157 practices then using the
SystmOne computerised record system (http://www.
tpp-uk.com/products/systmone), which permitted cen-
tralised data collection, to participate. We used opt-out
recruitment to reduce selection bias by facilitating
general practices’ agreement to share anonymised
patient data. Practices not wishing to share data could
opt out. Where practices had migrated from other
record systems, we included only full year data from
SystmOne to ensure data completeness for the periods
covered.
We collected patient data in 12-month segments span-
ning April to March to ensure complete data for each
Quality and Outcomes Framework (QOF) reporting
period.41 The QOF is a performance management
system whereby general practices are remunerated
according to achievement of targets reﬂecting quality of
care across four domains of clinical, organisational,
patient experience and additional services. We extracted
data on all patients registered with practices on 1st April
who were prescribed an opioid at any point in that year.
Within each 12-month segment, we excluded patients
under age 18 at the start of each year, patients with a
coded cancer diagnosis and patients with coded sub-
stance misuse or prescribed opioids normally used exclu-
sively to treat drug addiction (methadone and
sublingual buprenorphine).
Variables
Our dependent variables comprised long-term prescrib-
ing of any opioid and at least one prescription of a
strong opioid at any time point. We deﬁned long-term
use as a record of four or more opioid prescriptions
within a given study year, assuming an average duration
of 4 weeks supply for each prescription.42–44 We cate-
gorised opioid strength according to potency.45 The
‘weaker’ group included weak-to-moderate strength
opioids and comprised codeine (with or without para-
cetamol or ibuprofen), dihydrocodeine (with or without
paracetamol), tramadol, pethidine, meptazinol and
tapentadol. The ‘stronger’ opioids comprised diamor-
phine, morphine, oxycodone, fentanyl, hydromorphone,
buprenorphine (excluding preparations used for sub-
stance misuse), pentazocine, dipipanone and papavere-
tum. We deﬁned stronger opioid use as at least one
prescription of the latter group within the year.
Independent variables included patient-level and
practice-level factors we hypothesised or recognised
from earlier work to be associated with opioid prescrib-
ing.2 18 25 30 32–37 At the patient level, we examined
demographic, lifestyle, illness, prescribing and health
service utilisation variables. Demographic variables com-
prised age, gender and ethnicity. Lifestyle variables com-
prised alcohol use, smoking and body mass index
(BMI). We assigned patients with clinical codes asso-
ciated with alcohol use to one of two groups—problem
drinker and not a problem drinker. The problem
drinker group consisted of males recorded as drinking
50 units or more and females drinking 35 units or more
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per week. We also included those with clinical codes
indicating heavy use or referral to alcohol services. We
used the most recently recorded BMI in each year and
assigned patients accordingly as underweight (BMI
under 18.5), normal (18.5–25), overweight (25–30) and
obese (over 30).
Illness variables included pain-associated conditions
and clinical presentations, mental illness and comorbid-
ity. We reviewed diagnostic codes and used an iterative
process (involving BL, AH, RF and DP) to categorise
codes into three groups which we hypothesised might
affect GPs’ prescribing behaviour: deﬁnitively diagnosed
disease (eg, rheumatoid arthritis), clinical presentations
without a deﬁnite diagnosis (eg, ‘knee pain’) and
pain-associated syndromes with stronger psychosocial
features (eg, ﬁbromyalgia).
As a reﬂection of patient comorbidity and complexity,
we assessed polypharmacy using the number of different
repeat prescription medicines within a study year (1–4,
5–9 and 10 or more). We excluded prescriptions for
dressings, stoma equipment and medically indicated
food.
We assessed health service utilisation using general
practice consultations, missed appointments and special-
ist referrals. We could not distinguish which type of
healthcare provider patients consulted (eg, GP, practice
nurse). We summed general practice consultations and
missed appointments separately for each patient per
annum and categorised them as low (<5), medium
(between 5 and 10) and high (>10).
We categorised referrals by coded groups of destin-
ation specialty: diagnostic test (eg, X-ray), medicine,
musculoskeletal, neurology, specialist pain management
and surgery. We excluded codes used <100 times by all
participating general practices over the study period.
General practice-level variables comprised registered
patient list size, numbers of partners and salaried GPs,
and training status—all recorded as of 1 April 2011. We
used practice-level Index of Multiple Deprivation (IMD)
scores. The IMD measures area deprivation and is deter-
mined for each patient on the list, where available, and
then averaged over the practice. We used overall achieve-
ment in the QOF clinical domain as a proxy measure
for overall quality of care.
One consequence of collecting data coded within
each 12-month period is that we only captured clinical
codes entered within that year. For example, we could
capture whether a patient was coded as having an
alcohol or mental health problem within the year but
not if either was coded in earlier years. Our analysis was
therefore restricted to incident or rerecorded diagnoses
but did not include prevalent or previous diagnoses.
Data sources
The West and South Yorkshire and Bassetlaw
Commissioning Support Unit remotely extracted data
from participating SystmOne practices. The Unit also
supplied information on general practice characteristics.
Analysis
For our cross-sectional study, we analysed only 2011–
2012 data to examine short-term versus long-term and
stronger versus weaker opioid prescribing. This was to
avoid bias that would arise from studying later samples:
when practices changed from one patient record system
to another (SystmOne), they only migrated live patient
records, so patients that were alive early in our study
period but died before the practice changed records
system would have been omitted from the study.
For our longitudinal analysis of stepping up or down
between weaker and stronger opioids, we assembled a
cohort of patients prescribed an opioid during each of
4 years (2008–2012) and prescribed at least one strong
opioid during 1 or more but not all 4 years. We excluded
patients prescribed stronger opioids throughout all
4 years from the step-up analysis because they had no
opportunity to step up. We excluded patients prescribed
only weaker opioids from the step-down analysis since
they have no opportunity to step down. We did not
examine stepping up from none to weaker opioids as we
lacked complete records from prior years of patients not
prescribed opioids. We used the ﬁnal 4 years of data for
the analysis on trajectories for pragmatic reasons as it
delivered a sufﬁciently large data set of patients with
complete data.
We initially calculated unadjusted ORs and then
adjusted for confounders and clustering of patients
within practices. We modelled associations with long-
term and stronger opioid prescribing using multilevel
logistic regression with a random effect for practice to
account for clustering of patients within practices. We
found that practices coded ethnicity into 79 different
categories, making analysis potentially problematic. We
therefore classiﬁed ethnicity into four crudely aggre-
gated groups for cross-tabulation of ethnicity with opioid
strength and duration: British, Pakistani, other and
unknown. We included a random term for ethnicity for
the logistic regression modelling, permitting use of all of
the recorded ethnicity categories. We considered this to
be an efﬁcient and appropriate way to handle this vari-
able. Thus, we considered patients clustered within prac-
tice and within ethnicity.
We sought a parsimonious multivariate model to
ensure greater robustness of our ﬁndings. We ﬁtted
models to show effects adjusted for other covariates and
excluded covariates if their effect was negligible and did
not reach statistical signiﬁcance at the 5% level. For
adjusted ORs, if a covariate or factor was dropped to
achieve a more parsimonious model, then no OR is
reported.
Practice characteristics were strongly correlated with
one other as expected, with the number of GPs increas-
ing with list size. We also included practice IMD score in
the model. Partly for simplicity of interpretation, and
concerns over non-linearity, we treated all covariates as
categorical variables (eg, practice IMD). We judged that
any subsequent measurement error would be
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compensated for by greater ease of interpretation. We
generally used an ‘unknown’ category for missing vari-
ables (eg, BMI). For variables with very few missing
values (eg, age), we excluded patient records as increas-
ing the number of parameters would not have been suf-
ﬁciently compensated for by including larger numbers
of patient records.
We anticipated an interaction between sex and age
and accounted for this in the analysis. We handled age
in three categories: 18–49, 50–64 and over 65 years.
All analyses conducted used R statistical software, spe-
ciﬁcally Revolution R Open V.3.2.0, with the lme4 library
V.1.1.7 (R Core Team. R: A language and environment
for statistical computing. Secondary R: A language and
environment for statistical computing 2015. http://www.
R-project.org/).46
Study size
The sample size was originally based on the assumption
that we would recruit at least 70% of the then estimated
185 practices using SystmOne (later found to be only 157
practices), that is, 148 practices and around 800 000 regis-
tered patients in total. We assumed the prevalence of
repeat prescribing of (weaker and stronger) opioids was
around 5%, and that a sample size of ∼600 000 patients
over 18 years of age, even after allowing for clustering
within practices, would provide an accuracy within 0.5%.
This was based on an estimated design effect of 50 and
calculating two SDs. We anticipated that an effective
patient sample size of 12 000 would provide scope to
robustly estimate patient-level parameters for covariates
and factors. With 148 practices, we also anticipated good
scope to examine practice-level covariates, so that our
models could robustly estimate up to 14 practice-level cov-
ariates using the ratio of 10 observations per covariate.
RESULTS
Participants
One hundred and eleven (70.7%) practices shared
patient data. Participating practices had a higher
median number of all registered patients compared with
non-participants (7091 vs 5857; p=0.04), a higher mean
number of GPs (5 vs 4; p=0.04) and similar median prac-
tice IMD (33.7 vs 33.1; p=0.77).
The number of practices with available data rose from
43 in 2005–2006 to 111 in 2011–2012 (table 1). The
number of patients prescribed an opioid at least once
rose from 26 249 (6.6% of total adult patients) to 99 847
(12.8%) over the same period, and covered a total of
471 828 patient-years. We observed 471 828 patient-years
in which all patients included had received at least one
opioid prescription over the 7-year period.
For the 2011–2012 cross-sectional analysis, data for
almost all patients were complete. Data on gender were
unrecorded and treated as missing for three patients.
Some practice-level variables were unavailable for one
practice with 469 patients registered.
Of the sample, 60 776 (60.9%) were female, 41 016
(41.1%) aged 18–49 years at the start of the year, 26 460
(26.5%) 50–64 years and 32 371 (32.4%) 65 years or
over. Most were categorised as British (55 150; 55.2%),
while 11 464 (11.5%) were Pakistani, 10 802 (10.8%)
other and 22 431 (22.5%) of unknown ethnicity. Table 2
summarises other patient and practice characteristics.
Having earlier excluded patients with a code for cancer
or treatment for substance misuse, we categorised
37 508 (37.6%) as prescribed long-term opioids, equiva-
lent to 4.8% of the adult practice population. A total of
6605 (6.6%) of the sample were prescribed stronger
opioids, or 0.85% of adults.
The longitudinal analysis included 17 165 patients pre-
scribed any opioid in each of the 4 years considered. For
the analysis of stepping up to stronger opioids, we
excluded 810 patients prescribed stronger opioids for
each of the ﬁrst 3 years (2008–2011). Thus, there were
16 355 patients with three opportunities each to step up,
or 49 065 patient-years. Of these, 32 223 (65.7%) were
female, 12 354 (25.2%) aged 18–49 years, 16 343
(33.3%) 50–65 years and 20 866 (42.5%) 65 years or
over. Most patient-years were British (25 821; 52.6%),
while 8004 (16.3%) were Pakistani, 4844 (9.9%) other
and 10 515 (21.4%) of unknown ethnicity.
For the analysis of stepping down to weaker opioids, we
excluded those 14 918 patients prescribed weaker opioids
in the ﬁrst 3 years. After excluding 3 patients with incom-
plete data, there were 2244 patients, or 6732 patient-
years, available for the step-down analysis. Of these, 4662
(69.3%) were female, 1583 (23.5%) were aged
18–49 years, 2142 (31.8%) were 50–64 years and 3007
(44.7%) were 65 years or over. Most patient-years were
British (4160; 61.8%), while 480 (7.1%) were Pakistani,
4844 (9.9%) other and 1476 (21.9%) were of unknown
ethnicity. Table 3 summarises sample characteristics for
the longitudinal analyses.
Prescribing trends
The proportion of all patients prescribed a weaker
opioid at least once increased over 7 years from 6.5% to
12.4%, while the proportion prescribed a stronger
opioid at least once increased from 0.13% to 0.85%
(table 1). For patients prescribed any opioids, the pro-
portion prescribed stronger opioids increased from
4.0% to 13.7%.
Cross-sectional analyses
The odds of long-term against shorter term opioid pre-
scribing varied from 0.59 to 1.59 for practices, while
those for stronger opioid prescribing varied from 0.32 to
2.32, suggesting major inﬂuences of practice on pre-
scribing. None of the practice-level characteristics exam-
ined was associated with prescribing, except for practice
IMD for long-term prescribing (1.21; 1.09–1.35; table 4).
For ethnicity, the odds of long-term against shorter
term prescribing varied from 0.65 to 1.64, based on
85 223 patients with complete data on covariates. Plots
4 Foy R, et al. BMJ Open 2016;6:e010276. doi:10.1136/bmjopen-2015-010276
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of practice residuals and ethnicity residuals were consist-
ent with the assumption that the random effects fol-
lowed Gaussian distributions for the long-term
prescribing model. The ORs for stronger against weaker-
only opioid prescribing ranged from 0.50 to 2.29,
further indicating a strong association between ethnicity
and prescribing.
Compared with women aged 18–49 years, long-term
opioid prescribing was more likely in women aged 50–
64 years (adjusted OR 1.93, 95% CI 1.83 to 2.02) as was
stronger opioid prescribing (1.17, 1.06 to 1.29). These
associations were respectively stronger in women 65 and
over (2.39, 2.28 to 2.51; 1.46, 1.33 to 1.59).
Men below 50 years were more likely to be prescribed
long-term opioids than their corresponding female age
group (1.25, 1.18 to 1.32) with greater ORs for 50–
64 years (1.75, 1.65 to 1.84) and 65 and over (1.76, 1.67
to 1.86). Males aged 18–49 were more likely (1.82, 1.64
to 2.02) and those 65 and over less likely to be pre-
scribed stronger opioids (0.86, 0.78 to 0.96).
We found weak associations with coded diagnoses and
problems. Long-term and stronger prescribing were
associated with mental health problems (1.12, 1.03 to
1.23; 1.23, 1.06 to 1.23, respectively). Long-term and
stronger prescribing were also associated with deﬁni-
tively diagnosed disease (1.09, 1.05 to 1.14; 1.04, 1.04 to
1.20, respectively), while long-term prescribing was
inversely associated with clinical presentations lacking a
deﬁnitive diagnosis (0.83, 0.81 to 0.86). Being over-
weight or obese was inversely associated (0.87, 0.79 to
0.95) whereas being underweight was associated with
stronger opioid prescribing (1.89, 1.34 to 2.67).
Increasing polypharmacy was incrementally associated
with long-term and stronger opioid prescribing, with
adjusted ORs of 5.68 (5.35 to 6.03) and 6.55 (5.81 to
7.38), respectively, for those having 10 or more repeat
prescriptions.
Relative to patients attending up to 6 primary care
appointments over the year, those with 7–12 appoint-
ments were less likely to be prescribed long-term opioids
(0.90, 0.86 to 0.93), while those attending 12 or more
appointments were more likely to be prescribed long-
term and stronger opioids (1.07, 1.03 to 1.12; 2.03, 1.86
to 2.21, respectively). Long-term and stronger prescrib-
ing were also both more likely if patients had missed
booked primary care appointments, with the respective
ORs rising from 1.08 (1.04 to 1.12) and 1.12 (1.06 to
1.20) for one to two missed appointments to 1.31 (1.24
to 1.39) and 1.68 (1.53 to 1.84) for three or more.
Long-term prescribing was less likely for patients
referred for diagnostic tests (0.95, 0.90 to 0.99) and to
general medicine (0.87, 0.83 to 0.92) and more likely
for those referred to musculoskeletal services (1.19, 1.14
to 1.24). Long-term and stronger opioid prescribing
were associated with referrals to neurology (1.27, 1.15 to
1.40; 1.52, 1.32 to 1.75, respectively) and specialist pain
management services (3.70, 3.28 to 4.18; 5.74, 5.09 to
6.47, respectively).
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Table 2 Patient and practice characteristics for cross-sectional analysis of associations with long-term and stronger opioid
prescribing
Four or more opioids
prescriptions within year
(long term)
Strength of opioid prescribed at
any point within year
No (%) Yes (%) Weaker only (%) Stronger (%)
Number of patients 62 339 37 508 93 242 6 605
Patient demography
Female 18–49 yreas 19 455 (31.2) 5636 (15.0) 24 113 (25.9) 978 (14.8)
Female 50–64 years 8470 (13.6) 6802 (18.1) 14 239 (15.3) 1033 (15.6)
Female 65–100 years 9189 (14.7) 11 225 (29.9) 18 188 (19.5) 2226 (33.7)
Male 18–49 years 12 373 (19.8) 3549 (9.5) 15 104 (16.2) 818 (12.4)
Male 50–64 years 6561 (10.5) 4627 (12.3) 10 514 (11.3) 674 (10.2)
Male 65–100 years 6288 (10.1) 5669 (15.1) 11 081 (11.9) 876 (13.3)
Missing gender 3 (0) 3 (0)
Ethnicity
British 31 877 (51.1) 23 273 (62.0) 51 021 (54.7) 4129 (62.5)
Pakistani 8525 (13.7) 2939 (7.8) 11 226 (12.0) 238 (3.6)
Other 7718 (12.4) 3084 (8.2) 10 329 (11.1) 473 (7.2)
Unknown 14 219 (22.8) 8212 (21.9) 20 666 (22.2) 1765 (26.7)
Patient morbidity, behaviour and healthcare use
Mental health problem 1626 (2.6) 1156 (3.1) 2546 (2.7) 236 (3.6)
Definitively diagnosed disease 7359 (11.8) 6170 (16.4) 12 346 (13.2) 1183 (17.9)
Clinical presentation without a definite diagnosis 23 112 (37.1) 12 714 (33.9) 33 471 (35.9) 2355 (35.6)
Pain-associated syndrome 310 (0.5) 205 (0.5) 466 (0.5) 49 (0.7)
Alcohol problem 672 (1.1) 475 (1.3) 1055 (1.1) 92 (1.4)
Smoking 13 474 (21.6) 7173 (19.1) 19 422 (20.8) 1225 (18.5)
Body mass index
Overweight or obese 6573 (10.5) 3972 (10.6) 9972 (10.7) 573 (8.7)
Normal weight 3232 (5.2) 1510 (4.0) 4484 (4.8) 268 (4.0)
Underweight 251 (0.4) 149 (0.4) 357 (0.4) 43 (0.6)
Unknown 52 273 (83.8) 31 877 (85.0) 78 429 (84.1) 5721 (86.6)
Number of repeat prescriptions
0 15 066 (30.2) 4375 (11.9) 18 999 (23.6) 442 (7.3)
1–4 22 567 (45.2) 14 450 (39.4) 35 023 (43.5) 1994 (32.8)
5–9 8152 (16.3) 9759 (26.6) 16 280 (20.2) 1631 (26.9)
10–56 4150 (8.3) 8054 (22.0) 10 201 (12.7) 2003 (33.0)
Unknown 12 404 (19.9) 870 (2.3) 12 739 (13.7) 535 (8.1)
Number of consultations
0–6 21 530 (35.2) 8350 (22.8) 29 035 (31.7) 845 (14.0)
7–12 19 810 (32.4) 10 647 (29.0) 29 174 (31.8) 1283 (21.2)
13–366 19 689 (32.3) 17 677 (48.2) 33 451 (36.5) 3915 (64.8)
Unknown 1310 (2.1) 834 (2.2) 1582 (1.7) 562 (8.5)
Number of missed appointments
0 39 295 (63.0) 22 556 (60.1) 58 532 (62.7) 3319 (50.2)
1–2 17 197 (27.6) 10 756 (28.7) 26 061 (28.0) 1892 (28.6)
3–29 4537 (7.3) 3362 (9.0) 7067 (7.6) 832 (12.6)
Unknown 1310 (2.1) 834 (2.2) 1582 (1.7) 562 (8.5)
Referrals
Diagnostic testing 6207 (10.0) 4368 (11.6) 9794 (10.5) 781 (11.8)
Medical specialty 5446 (8.7) 4317 (11.5) 8856 (9.5) 907 (13.7)
Musculoskeletal specialty 9370 (15.0) 6926 (18.5) 15 009 (16.1) 1287 (19.5)
Neurology 1126 (1.8) 1046 (2.8) 1890 (2.0) 282 (4.3)
Specialist pain management 460 (0.7) 1135 (3.0) 1070 (1.1) 525 (7.9)
Surgical specialty 3824 (6.1) 2598 (6.9) 5877 (6.3) 545 (8.2)
Practice characteristics
List size
1500–6999 22 869 (36.7) 12 461 (33.2) 33 133 (35.5) 2197 (33.3)
7000–10 999 20 127 (32.3) 12 884 (34.4) 30 855 (33.1) 2156 (32.6)
11 000–25 112 19 343 (31.0) 12 163 (32.4) 29 254 (31.4) 2252 (34.1)
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Longitudinal analyses
The odds of stepping up against not stepping up to a
stronger opioid varied markedly from 0.31 to 3.36 by
practice but less so, from 0.91 to 1.06, for stepping
down. Practice-level variables explained none of the vari-
ation (table 5). There were variations by ethnic category,
with ORs ranging from 0.55 to 1.40 for stepping up and
0.87 to 1.24 for stepping down. Compared with women
aged 18–49 years, men aged 65 and over were less likely
to step up to a stronger opioid (0.77, 0.63 to 0.94), while
those aged 18–49 years were less likely to step down
(0.53, 0.37 to 0.75).
Stepping up was associated with coded deﬁnitive diag-
noses (1.64, 1.46 to 1.85), clinical presentations lacking
a deﬁnitive diagnosis (1.60, 1.43 to 1.79) and being
underweight (3.26, 1.49 to 7.17). Increasing polyphar-
macy (4.15, 3.26 to 5.29 for 10 or more repeat prescrip-
tions) was strongly associated with stepping up and
inversely associated with stepping down (0.60, 0.46 to
0.77 for those with 10 or more prescriptions). Increasing
numbers of primary care appointments were also asso-
ciated with stepping up, with the OR reaching 3.04 (2.48
to 3.73) for over 12 appointments in the year.
Referrals to neurology and specialist pain manage-
ment services were associated with stepping up (1.77,
1.42 to 2.21; 5.17, 4.37 to 6.12, respectively) and
inversely associated with stepping down (0.59, 0.38 to
0.91; 0.61, 0.45 to 0.83, respectively). Referrals to
general medicine (1.17, 1.02 to 1.34), musculoskeletal
services (1.48, 1.31 to 1.66) and surgery (1.29, 1.09 to
1.52) were also associated with stepping up.
Table 6 provides an overall summary of our ﬁndings.
DISCUSSION
Opioid prescribing in primary care has risen markedly,
even after excluding patients with a code for cancer or
drug dependence. The proportion of all patients pre-
scribed a weaker opioid at least once almost doubled
over 7 years, while the proportion prescribed a stronger
opioid increased over sixfold. Much of this prescribing
was to patients with unspeciﬁed non-malignant pain
rather than to those with recorded diagnoses of a spe-
ciﬁc disease. We identiﬁed substantial, poorly explained
variation among general practices in long-term and
stronger opioid prescribing, particularly in the
Table 2 Continued
Four or more opioids
prescriptions within year
(long term)
Strength of opioid prescribed at
any point within year
No (%) Yes (%) Weaker only (%) Stronger (%)
Practice Index of Multiple Deprivation
7–26.7 21 518 (34.5) 13 248 (35.3) 32 251 (34.6) 2515 (38.1)
26.7–39.5 20 029 (32.1) 12 506 (33.3) 30 129 (32.3) 2406 (36.4)
39.5–57.5 20 792 (33.4) 11 754 (31.3) 30 862 (33.1) 1684 (25.5)
Number of GPs
0–4 25 852 (41.5) 14 305 (38.1) 37 645 (40.4) 2512 (38.0)
5–9 18 129 (29.1) 11 607 (30.9) 27 757 (29.8) 1979 (30.0)
9–20 18 358 (29.4) 11 596 (30.9) 27 840 (29.8) 2114 (32.0)
Proportion of salaried GPs
0–16.7% 20 779 (33.3) 12 422 (33.1) 30 807 (33.0) 2394 (36.2)
16.7–40% 23 030 (36.9) 14 097 (37.6) 34 759 (37.3) 2368 (35.8)
40% and over 18 172 (29.2) 10 878 (29.0) 27 222 (29.2) 1828 (27.7)
Unknown 358 (0.6) 111 (0.3) 454 (0.5) 15 (0.2)
Patients per GP
707–1278 21 638 (34.7) 13 670 (36.4) 33 052 (35.4) 2256 (34.2)
1279–1558 19 744 (31.7) 12 603 (33.6) 29 847 (32.0) 2500 (37.8)
1559–4447 20 599 (33.0) 11 124 (29.6) 29 889 (32.0) 1834 (27.8)
Unknown 358 (0.6) 111 (0.3) 454 (0.5) 15 (0.2)
Proportion of ‘first five’ GPs
0 34 016 (54.6) 20 291 (54.1) 50 462 (54.1) 3845 (58.2)
10–27.3% 10 762 (17.3) 6705 (17.9) 16 407 (17.6) 1060 (16.0)
27.3–66.7% 17 203 (27.6) 10 401 (27.7) 25 919 (27.8) 1685 (25.5)
Unknown 358 (0.6) 111 (0.3) 454 (0.5) 15 (0.2)
Teaching status 26 323 (42.2) 16 118 (43.0) 39 319 (42.2) 3122 (47.3)
Total QOF clinical domain points
243–647 21 583 (34.6) 12 859 (34.3) 32 281 (34.6) 2161 (32.7)
648–657 21 630 (34.7) 13 052 (34.8) 32 330 (34.7) 2352 (35.6)
658–661 19 126 (30.7) 11 597 (30.9) 28 631 (30.7) 2092 (31.7)
GP, general practitioner; QOF, Quality and Outcomes Framework.
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Table 3 Patient and practice characteristics for longitudinal step-up and step-down analyses
Stepping up to stronger
opioids
Stepping down from
stronger opioids
Yes (%) No (%) Yes (%) No (%)
Number of patient years 1 662 47 403 937 5 795
Patient demography
Female 18–49 years 255 (15.3) 8174 (17.2) 137 (14.6) 879 (15.2)
Female 50–64 years 317 (19.1) 9642 (20.3) 196 (20.9) 1181 (20.4)
Female 65–100 years 600 (36.1) 13 235 (27.9) 354 (37.8) 1915 (33.0)
Male 18–49 years 117 (7.0) 3808 (8.0) 45 (4.8) 552 (9.5)
Male 50–64 years 181 (10.9) 5705 (12.0) 92 (9.8) 673 (11.6)
Male 65–100 years 192 (11.6) 6839 (14.2) 113 (12.0) 625 (10.8)
British 1045 (62.9) 24 776 (52.3) 542 (57.8) 3618 (62.4)
Pakistani 119 (7.2) 7885 (16.6) 91 (9.7) 389 (6.7)
Other 157 (9.4) 4687 (9.9) 101 (10.8) 515 (8.9)
Unknown 341 (20.5) 10 174 (21.5) 203 (21.7) 1273 (22.0)
Patient morbidity, behaviour and healthcare use
Mental health problem 72 (4.3) 1661 (3.5) 35 (3.7) 218 (3.8)
Definitively diagnosed disease 493 (29.7) 7493 (15.8) 186 (19.8) 1127 (19.4)
Clinical presentation without a definite diagnosis 900 (54.2) 18 366 (38.7) 384 (41.0) 2442 (42.1)
Pain-associated syndrome 21 (1.3) 341 (0.7) 8 (0.8) 55 (0.9)
Alcohol problem 17 (1.0) 1645 (3.5) 4 (0.4) 43 (0.7)
Smoking 194 (11.7) 5147 (10.8) 94 (10.0) 660 (11.4)
Body mass index
Normal 43 (4.8) 1 192 (2.5) 25 (2.7) 166 (2.9)
Overweight or obese 118 (7.1) 3166 (6.7) 63 (6.7) 360 (6.2)
Underweight 9 (0.5) 85 (0.2) 0 (0) 18 (0.3)
Unknown 1 492 (90.0) 42 960 (90.6) 849 (90.6) 5251 (90.6)
Number of repeat prescriptions
None 90 (5.4) 7836 (16.5) 98 (10.4) 431 (7.4)
1–4 495 (29.8) 19 609 (41.4) 318 (3.4) 1908 (33.0)
5–9 507 (30.5) 11 492 (24.2) 248 (2.6) 1594 (27.5)
10–56 570 (34.3) 8466 (17.8) 273 (29.1) 1862 (32.1)
Number of consultations
0–6 117 (7.0) 11 122 (23.5) 132 (1.3) 800 (13.8)
7–12 298 (17.9) 14 415 (30.4) 224 (23.9) 1270 (21.9)
13–366 1247 (75.0) 21 866 (46.1) 581 (62.0) 3725 (64.3)
Number of missed appointments
0 903 (54.3) 28 482 (60.0) 543 (58.0) 3302 (57.0)
1–2 564 (33.9) 14 267 (30.1) 297 (31.7) 1793 (30.9)
3–29 195 (11.7) 4654 (9.8) 97 (10.4) 700 (12.1)
Referrals
Diagnostic testing 164 (9.9) 3384 (7.1) 80 (8.5) 491 (8.5)
Medical specialty 303 (18.2) 5200 (11.0) 141 (15.0) 863 (14.9)
Musculoskeletal specialty 470 (28.3) 6710 (14.2) 198 (21.1) 1100 (19.0)
Neurology 107 (6.4) 1073 (2.3) 22 (2.3) 249 (4.3)
Specialist pain management 220 (13.2) 919 (1.9) 47 (5.0) 494 (8.5)
Surgical specialty 186 (11.2) 3051 (6.4) 85 (9.1) 513 (8.8)
Practice characteristics
List size
1496–6999 21 563 (45.5) 679 (40.8) 2337 (40.3) 427 (45.6)
7000–11 000 14 959 (31.6) 563 (33.9) 2021 (34.9) 292 (31.2)
11 000–25 112 10 881 (23.0) 420 (25.3) 1437 (24.8) 218 (23.2)
Practice Index of Multiple Deprivation
6.7–26.6 12 507 (26.4) 504 (30.3) 1711 (29.5) 267 (28.5)
26.7–39.4 16 270 (34.2) 669 (40.2) 2480 (42.8) 366 (39.1)
39.5–60 18 626 (39.3) 489 (29.4) 1604 (27.7) 304 (32.4)
Number of GPs
0–4 18 496 (39.0) 566 (34.1) 1938 (33.4) 369 (39.4)
5–9 20 316 (42.9) 774 (46.6) 2638 (45.5) 416 (44.4)
Continued
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likelihood of stepping up to stronger opioids.
Prescribing patterns varied by age, gender and ethnicity
and suggested different risk groups; almost a third of all
long-term opioid prescribing and of strong opioid pre-
scribing occurred in women 65 and over. Younger men
were particularly more likely to experience long-term
and stronger opioid prescribing and less likely to step
down once prescribed stronger opioids.
Our ﬁndings are based on a large sample of relatively
unselected primary care patients from diverse UK metro-
politan populations. While there is now a sizeable litera-
ture on risk factors for long-term or stronger opioid
prescribing,2 9 23 25–27 29–31 less is known about patient
trajectories. We found that stepping up from weaker to
stronger opioids was most strongly associated with poly-
pharmacy, more frequent primary care attendances,
being underweight and pain service referrals. Patients
were likely to step up regardless of whether or not
painful conditions were deﬁnitively diagnosed, but those
with no deﬁnitive physical diagnosis were less likely to be
prescribed longer term opioids.
Our study has several limitations. First, we cannot
imply causation from association. For example, patients
with a coded mental health problem could be more
likely to be prescribed an opioid or they could have
developed a mental health problem as a result of
chronic pain for which they were prescribed an opioid.
Second, our exploratory work involved multiple statis-
tical testing, increasing the risk of type 1 errors and
hence falsely positive associations. Third, we recognised
the potential for misclassiﬁcation bias from our use of
routinely recorded and coded data. For example,
although musculoskeletal presentations to GPs are
recorded in patient notes in 85% of such encounters,
they are only clinically coded 32% of the time.47
Under-recording may have been more likely for diagno-
ses and clinical ﬁndings associated with stigmatisation
(eg, mental illness, alcohol misuse). We anticipated that
such imperfectly and incompletely coded data would
reduce the identiﬁcation and strength of any true asso-
ciations. However, we sought typically recorded data in a
typical sample of practices to enhance generalisability to
other UK general practices and the utility of our ﬁnd-
ings. Any subsequent intervention to change prescribing
practice based on searches of patient records would
need to work in ‘real-world’ practices rather than those
selected for better quality coding. Further imprecision
was caused by our use of practice-level rather than
patient-level deprivation. Fourth, we used data from only
one practice computerised record system. Practice use of
SystmOne is associated with higher QOF achievement; it
is not known whether particular system characteristics
facilitate higher quality of care, better data recording or
both.48 This may be of limited relevance to our study as
our dependent variables were not directly related to
QOF targets. Fifth, the detection and magnitude of asso-
ciations concerning diagnostic codes was reduced by
ascertainment bias because we could only capture diag-
noses and events recorded within each 12-month
period. Subsequently, the strengths of associations
related to mental health problems, alcohol problems
and pain-related diagnoses were less than those found in
other studies.2 27 30 33 35 37 Conversely, including ‘ever-
coded’ problems would have overestimated current diag-
noses. Sixth, our models excluded patients with missing
covariates; patients with missing data may systematically
differ from those with complete data. Seventh, model
selection was achieved through backwards stepwise selec-
tion, with careful attention paid to collinearity. This may
have led to a model with optimistic goodness-of-ﬁt
characteristics (the R2 value will be too high) and for
exaggerated coefﬁcients that would be improved by
shrinkage. These issues are unlikely to substantially alter
the conclusions of our exploratory work. Eighth, partici-
pating practices were likely to be larger and have more
primary care physicians than non-participating practices.
Although smaller practice list size is associated with
higher levels of high-risk prescribing,39 our adjusted ana-
lyses did not ﬁnd a relationship between practice size
and opioid prescribing. Ninth, the smaller sample size
limited the precision of the step-down analysis and
ability to detect associations of modest magnitude.
The prescribing patterns we found reﬂect varying
interactions between population need and one or more
of patient, clinician and health system behaviour. In
women, long-term and stronger opioid prescribing
increased with age, probably reﬂecting increasing popu-
lation burden and impact of musculoskeletal disorders.
Table 3 Continued
Stepping up to stronger
opioids
Stepping down from
stronger opioids
Yes (%) No (%) Yes (%) No (%)
10–20 8591 (18.1) 322 (19.4) 1219 (21.0) 152 (16.2)
Teaching status 18 803 (39.7) 763 (45.9) 2629 (45.4) 371 (39.6)
Total QOF clinical domain points within each year
404–654 16 245 (34.3) 482 (29.0) 1550 (26.7) 275 (29.4)
655–677 15 569 (32.8) 544 (32.7) 1914 (33.0) 316 (33.7)
678–697 15 589 (32.9) 636 (38.3) 2331 (40.2) 346 (36.9)
GP, general practitioner; QOF, Quality and Outcomes Framework.
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Table 4 Cross-sectional analysis of associations with long-term and stronger opioid prescribing
Four or more opioids prescriptions
within year (long term)
Stronger opioid prescription at any
point within year
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Patient demographics
Female 18–49 years 1 1 1 1
Female 50–64 years 2.77 (2.65 to 2.90) 1.93 (1.83 to 2.02) 1.79 (1.64 to 1.96) 1.17 (1.06 to 1.29)
Female 65–100 years 4.22 (4.05 to 4.39) 2.39 (2.28 to 2.51) 3.02 (2.79 to 3.26) 1.46 (1.33 to 1.59)
Male 18–49 years 0.99 (0.94 to 1.04) 1.25 (1.18 to 1.32) 1.34 (1.21 to 1.47) 1.82 (1.64 to 2.02)
Male 50–64 years 2.43 (2.32 to 2.55) 1.75 (1.65 to 1.84) 1.58 (1.43 to 1.75) 1.07 (0.96 to 1.19)
Male 65–100 years 3.11 (2.97 to 3.26) 1.76 (1.67 to 1.86) 1.95 (1.77 to 2.14) 0.86 (0.78 to 0.96)
British 1 Random effect 1 Random effect
Pakistani 0.47 (0.45 to 0.49) Random effect 0.26 (0.23 to 0.30) Random effect
Other 0.55 (0.52 to 0.57) Random effect 0.57 (0.51 to 0.62) Random effect
Unknown 0.79 (0.77 to 0.82) Random effect 1.06 (1.00 to 1.19) Random effect
Patient morbidity, behaviour and healthcare use
Mental health problem 1.19 (1.10 to 1.28) 1.12 (1.03 to 1.23) 1.32 (1.15 to 1.51) 1.23 (1.06 to 1.43)
Definitively diagnosed disease 1.47 (1.42 to 1.53) 1.09 (1.05 to 1.14) 1.43 (1.34 to 1.54) 1.12 (1.04 to 1.20)
Clinical presentation without a definite
diagnosis
0.87 (0.85 to 0.89) 0.83 (0.81 to 0.86) 0.99 (0.94 to 1.04) –
Pain-associated syndrome 1.10 (0.92 to 1.31) – 1.49 (1.11 to 2.00) –
Body mass index
Overweight or obese 1.01 (0.96 to 1.05) – 0.79 (0.73 to 0.87) 0.87 (0.79 to 0.95)
Underweight 0.99 (0.81 to 1.21) – 1.71 (1.24 to 2.34) 1.89 (1.34 to 2.67)
Number of repeat prescriptions
1–4 2.21 (2.12 to 2.29) 2.05 (1.96 to 2.14) 2.45 (2.20 to 2.72) 2.06 (1.85 to 2.30)
5–9 4.12 (3.94 to 4.31) 3.65 (3.47 to 3.84) 4.31 (3.87 to 4.79) 3.51 (3.13 to 3.95)
10–56 6.68 (6.36 to 7.03) 5.68 (5.35 to 6.03) 8.44 (7.59 to 9.38) 6.55 (5.81 to 7.38)
Number of consultations
0–6 1 1 1 1
7–12 1.39 (1.34 to 1.44) 0.9 (0.86 to 0.93) 1.51 (1.38 to 1.65) 1.1 (1.00 to 1.20)
13–366 1.37 (1.35 to 1.38) 1.07 (1.03 to 1.12) 4.02 (3.73 to 4.34) 2.03 (1.86 to 2.21)
Number of missed appointments
0 1 1 1 1
1–2 1.19 (1.06 to 1.12) 1.08 (1.04 to 1.12) 1.28 (1.21 to 1.36) 1.12 (1.06 to 1.20)
3–29 1.29 (1.23 to 1.35) 1.31 (1.24 to 1.39) 2.08 (1.92 to 2.25) 1.68 (1.53 to 1.84)
Referrals
Diagnostic testing 1.19 (1.14 to 1.24) 0.95 (0.90 to 0.99) 1.14 (1.06 to 1.24) –
Medical specialty 1.36 (1.30 to 1.42) 0.87 (0.83 to 0.92) 1.52 (1.41 to 1.63) –
Musculoskeletal specialty 1.28 (1.24 to 1.33) 1.19 (1.14 to 1.24) 1.26 (1.18 to 1.34) –
Neurology 1.56 (1.43 to 1.70) 1.27 (1.15 to 1.40) 2.16 (1.90 to 2.45) 1.52 (1.32 to 1.75)
Specialist pain management 4.2 (3.76 to 4.68) 3.7 (3.28 to 4.18) 7.44 (6.68 to 8.28) 5.74 (5.09 to 6.47)
Surgical specialty 1.14 (1.08 to 1.20) – 1.34 (1.22 to 1.47) –
Practice characteristics
List size
1500–6999 1 – 1 –
7000–10 999 1.18 (1.13 to 1.21 – 1.05 (0.99 to 1.12) –
11 000–25 112 1.15 (1.12 to 1.19) – 1.16 (1.09 to 1.23) –
Practice Index of Multiple Deprivation
7–26.7 1 1 1 –
26.7–39.5 1.01 (0.98 to 1.05) 1.17 (1.04 to 1.31) 1.02 (0.97 to 1.09) –
39.5–57.5 0.92 (0.89 to 0.95) 1.21 (1.09 to 1.35) 0.7 (0.66 to 0.75) –
Number of GPs
0–4 1 – 1 –
5–9 1.16 (1.12 to 1.19) – 1.07 (1.01 to 1.14) –
9–20 1.14 (1.11 to 1.18) – 1.14 (1.07 to 1.21) –
Proportion of salaried GPs
Lower third 1 – 1 –
Middle third 1.02 (0.99 to 1.06) 0.88 (0.83 to 0.93) –
Upper third 1 (0.97 to 1.03) 0.86 (0.81 to 0.92) –
Continued
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The relative risk of stronger opioid prescribing was
highest in younger men whereas older men were less
likely to step up to and be prescribed stronger opioids.
Younger men are prone to riskier and more severe acci-
dental injuries.49 However, our ﬁnding that they were
less likely to step down from stronger to weaker opioids
is also compatible with an explanation of under-
recognised or under-recorded opioid dependence.
There were consistent and large variations in prescrib-
ing by ethnicity. Patients coded as Pakistani or other eth-
nicities were particularly less likely than those coded as
British to be prescribed long-term and stronger opioids,
less likely to step up and more likely to step down. This
is harder to explain according to population need and
suggests a range of patient and clinician inﬂuences,
including patient–clinician interactions.
We examined different ways of coding painful condi-
tions to explore the inﬂuence of clinician certainty
about diagnosis. Many musculoskeletal presentations are
self-limiting but those of longer durations eventually
acquire a diagnostic label. This is reﬂected in our
ﬁnding that long-term and stronger opioid prescribing
and stepping up were all associated with deﬁnitively
diagnosed conditions (eg, osteoarthritis). Long-term
prescribing was less likely for clinical presentations
without a deﬁnitive diagnosis (eg, knee pain); the associ-
ation with stepping up in this group may partly reﬂect
additional symptomatic coding for exacerbations of
deﬁnitively diagnosed conditions. However, we found no
such associations for the smaller group of patients cate-
gorised as having pain associated syndromes with stron-
ger psychosocial features (eg, ﬁbromyalgia). The wider
CIs suggest type 2 error but this ﬁnding may also reﬂect
clinician reluctance to prescribe opioids without an
obvious physical explanation. We could not determine
how much opioid prescribing occurred before or as a
consequence of specialist referrals; however, the associ-
ation with referrals to neurology suggest that patients
and GPs may struggle to ﬁnd explanations for pain
symptoms.
The association with coded mental health problems is
consistent with an explanation that opioid prescribing
occurs in response to psychological distress while also
causing further dysphoria.
Some ﬁndings can only invite more speculative expla-
nations. Being underweight was associated with stepping
up to stronger opioids. This may reﬂect deterioration of
long-term conditions, anorexia associated with taking
stronger opioids or omitted codes for end-of-life care or
drug dependence.
We found strong associations between increasing poly-
pharmacy, which reﬂects multimorbidity, and all of long-
term, stronger and stepping up opioid prescribing.
Multimorbidity affects over a ﬁfth of patients in primary
care;50 osteoarthritis and cardiometabolic conditions
(eg, hypertension, diabetes) are the mostly commonly
paired.51 This complicates clinical management, such as
prescribing decisions,52 and presents challenges for
planning care, especially given that an average consult-
ation covers 2.5 problems in 11.9 min.47 While patterns
of opioid prescribing may partly reﬂect perceived clin-
ical need, decisions to prescribe stronger opioids are
often made reactively without explicitly assessing addic-
tion risk or clear action planning.53
Only practice-level deprivation partly accounted for
marked variation in prescribing patterns between
general practices. Differences among practices in
approaches to prescribing cannot be attributed to rou-
tinely recorded organisational characteristics such as the
number of GPs in each practice or QOF achievement.
Practice team and individual clinician behaviours, which
appear poorly represented by routinely available
Table 4 Continued
Four or more opioids prescriptions
within year (long term)
Stronger opioid prescription at any
point within year
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Patients per GP
707–1278 1 – 1 –
1279–1558 1.01 (0.98 to 1.04) 1.23 (1.16 to 1.3) –
1559–4447 0.86 (0.83 to 0.88) 0.9 (0.84 to 0.96) –
Proportion of ‘first five’ GPs
Lower third 1 – 1 –
Middle third 1.04 (1.01 to 1.08) – 0.85 (0.79 to 0.91) –
Upper third 1.01 (0.98 to 1.04) – 0.83 (0.8 to 0.9) –
Teaching status 1.03 (1.01 to 1.06) 1.23 (1.17 to 1.29) –
Total QOF clinical domain points
243–647 1 – 1 –
648–657 1.01 (0.99 to 1.04) 1.09 (1.02 to 1.15) –
658–661 1.02 (0.99 to 1.02) 1.09 (1.03 to 1.16) –
Bold typeface represent odds ratios for which the 95% confidence intervals did not cross 1.
GP, general practitioner; QOF, Quality and Outcomes Framework.
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Table 5 Longitudinal step-up and step-down analyses
Stepping up to stronger opioids Stepping down from stronger opioids
Unadjusted OR (95% CI) Adjusted OR (95% CI) Unadjusted OR (95% CI) Adjusted OR (95% CI)
Patient demography
Female 18–49 years 1 1 1 1
Female 50–64 years 1.05 (0.89 to 1.25) 0.94 (0.79 to 1.12) 1.07 (0.84 to 1.35) 1.07 (0.84 to 1.35)
Female 65–100 years 1.45 (1.25 to 1.69) 1.17 (1.00 to 1.38) 1.19 (0.96 to 1.47) 1.21 (0.97 to 1.50)
Male 18–49 years 0.99 (0.79 to 1.23) 1.21 (0.96 to 1.52) 0.55 (0.39 to 0.79) 0.53 (0.37 to 0.75)
Male 50–64 years 1.02 (0.84 to 1.23) 0.97 (0.79 to 1.19) 0.88 (0.66 to 1.16) 0.90 (0.68 to 1.20)
Male 65–100 years 0.9 (0.74 to 1.09) 0.77 (0.63 to 0.94) 1.16 (0.89 to 1.52) 1.20 (0.91 to 1.58)
British 1 Random effect Random effect
Pakistani 0.36 (0.30 to 0.44) Random effect 1.56 (1.22 to 2.00) Random effect
Other 0.79 (0.67 to 0.94) Random effect 1.31 (1.04 to 1.65) Random effect
Unknown 0.8 (0.70 to 0.90) Random effect 1.06 (0.90 to 1.27) Random effect
Patient morbidity, behaviour and healthcare use
Mental health problem 1.25 (0.98 to 1.59) – 0.99 (0.69 to 1.43) –
Definitively diagnosed disease 2.25 (2.02 to 2.50) 1.64 (1.46 to 1.85) 1.03 (0.86 to 1.22) –
Clinical presentation without a definite diagnosis 1.87 (1.69 to 2.06) 1.60 (1.43 to 1.79) 0.95 (0.83 to 1.10) –
Pain-associated syndrome 1.76 (1.13 to 2.74) – 0.90 (0.43 to 1.89) –
Alcohol problem 1.13 (0.69 to 1.84) – 0.57 (0.21 to 1.60) –
Smoking 1.09 (0.93 to 1.26) – 0.87 (0.69 to 1.09) –
Body mass index
Normal 1 1 1 –
Overweight 0.93 (0.62 to 1.40) 0.95 (0.62 to 1.45) 1.05 (0.60 to 1.84) –
Obese 1.13 (0.77 to 1.67) 1.08 (0.72 to 1.62) 1.31 (0.74 to 2.32) –
Underweight 2.94 (1.39 to 6.22) 3.26 (1.49 to 7.17) – –
Weight unrecorded 0.96 (0.71 to 1.31) 0.91 (0.66 to 1.25) 1.07 (0.70 to 1.65) –
Number of repeat prescriptions
None 1 1 1 1
1–4 2.2 (1.75 to 2.76) 1.66 (1.32 to 2.09) 0.73 (0.57 to 0.94) 0.71 (0.55 to 0.91)
5–9 3.84 (3.06 to 4.82) 2.8 (2.21 to 3.54) 0.68 (0.53 to 0.89) 0.66 (0.51 to 0.86)
10–56 5.86 (4.68 to 7.34) 4.15 (3.26 to 5.29) 0.65 (0.50 to 0.83) 0.60 (0.46 to 0.77)
Number of consultations
0–6 1 1 1 –
7–12 1.97 (1.59 to 2.44) 1.52 (1.22 to 1.88) 1.07 (0.85 to 1.35) –
13–366 5.42 (4.48 to 6.56) 3.04 (2.48 to 3.73) 0.95 (0.77 to 1.16) –
Number of missed appointments
0 1 1 1 1
1–2 1.25 (1.12 to 1.39) – 1.01 (0.87 to 1.17) –
3–29 1.32 (1.13 to 1.55) – 0.84 (0.67 to 1.06) –
Referrals
Medical specialty 1.81 (1.59 to 2.06) 1.17 (1.02 to 1.34) 1.01 (0.84 to 1.23) –
Musculoskeletal specialty 2.39. 2.14 to 2.67) 1.48 (1.31 to 1.66) 1.14 (0.97 to 1.36) –
Neurology 2.97 (2.42 to 3.65) 1.77 (1.42 to 2.21) 0.54 (0.34 to 0.83) 0.59 (0.38 to 0.91)
Specialist pain management 7.72 (6.60 to 9.02) 5.17 (4.37 to 6.12) 0.57 (0.42 to 0.77) 0.61 (0.45 to 0.83)
Surgical specialty 1.83 (1.57 to 2.14) 1.29 (1.09 to 1.52) 1.03 (0.81 to 1.31) –
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indicators, are likely to account for substantial levels of
variations in opioid prescribing. These may include
established norms and procedures for reviewing pre-
scribing, policies promoting continuity of care and
adherence to best practice guidance on opioid prescrib-
ing.54 We further recognise the likely inﬂuence of wider
system and social factors on prescribing, such as local
prescribing formularies, legislation on controlled sub-
stances and media coverage.
Current prescribing trends signal a need for a con-
certed response to what is likely to be ineffective and
harmful treatment for a large proportion of primary
care patients. Once patients with coded cancer or sub-
stance dependence are accounted for, around 1 in 20 of
the adult practice population is prescribed long-term
opioids, a mean of 338 patients per practice. Nearly 1 in
100, or 59 adults per practice, are prescribed stronger
opioids. Healthcare systems need to respond to two
related problems: how to improve care for patients with
chronic non-cancer pain; and how best to curb and
reverse current trends in opioid prescribing, especially
of stronger opioids.
One response is to recognise and manage chronic pain
as a long-term condition which requires coordinated care
including the formulation of care plans agreed between
professionals and patients, effective non-pharmacological
and self-management strategies, and ongoing active mon-
itoring. We have demonstrated that it is feasible to iden-
tify patients within primary care based on prescribing
records, potentially stratifying those at highest risk of step-
ping up to stronger opioid treatment as a priority group.
These patient groups may extend beyond those with
recognised and more severe chronic non-cancer pain.
Patients with multimorbidity and polypharmacy represent
the most obvious and pressing target for ‘deprescrib-
ing’.55 While we would not advocate non-negotiated
reductions of regular modest prescriptions of weaker
opioids, patients should be alerted to potential risks of
continuing treatment at medication reviews.
Another response is to reduce initiation of opioid pre-
scribing. Given the accumulating evidence about their
harms, reversing the current trend in opioid prescribing
is likely to beneﬁt a substantial at-risk population. There
are at least two evidence-based approaches to address
this at practice level. First, audit and feedback is effective
at changing professional practices.56 Its effects may be
relatively modest but audit and feedback can be con-
ducted efﬁciently using routinely recollected data and
its effects may be enhanced by targeting higher baseline
non-compliance with standards (eg, higher prescribing
practices) and incorporating action plans for practices.
Second, computerised prompts triggered by combina-
tions of patient characteristics associated with stepping
up to stronger opioids could alert clinicians to recon-
sider opioid prescribing at the point of care.
Computerised clinical decision support is more likely to
be effective if clinicians are required to supply a reason
for over-riding advice.57
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There is a growing consensus on best practice when
considering or initiating opioids.58–60 This includes
recognising and dealing with psychosocial aspects of
pain, managing patient expectations about the degree of
pain relief likely to be achievable, starting with a thera-
peutic trial and an agreement to stop or reduce opioids
when they do not work, and recording care plans agreed
with patients to guide all subsequent prescribers in main-
taining the plan. GPs should avoid escalation above
120 mg morphine-equivalent daily equivalent and refer
to pain management services if this seems likely.60
Strategies to bring about large-scale change in health-
care are unlikely to succeed if they fail to address mul-
tiple barriers and enablers across different levels of
healthcare systems.61 Therefore, these types of above
responses need to be coupled with educational cam-
paigns to challenge or change professional and patient
beliefs and expectations about opioid prescribing,
drawing on lessons learned so far from strategies to
reduce inappropriate prescribing of medicines such as
antibiotics and minor hypnotics.62
Future research efforts should address strategies to
reduce opioid prescribing which target patients and clin-
icians. There is little evidence on the effectiveness of
interventions to reduce opioid prescribing in patients
with chronic non-cancer pain.63 Non-pharmacological
alternatives to pain management may be modestly bene-
ﬁcial but require further development and evaluation.64
There are parallel needs to further understand practice-
level variation and evaluate interventions primarily
aimed at clinicians to discourage initiation or continu-
ation of opioid prescribing.
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Table 6 Overall summary of associations with long-term and stronger opioid prescribing (+=adjusted OR of 1–2; ++=OR of
2–3; +++=OR over 3; italics=OR <1)
Associations with
long-term opioid
prescribing
Associations with
prescribing of
stronger opioids
Associations with
stepping up from
weaker to stronger
opioids
Associations with stepping
down from stronger to
weaker opioids
Age and
gender
Female 50–64+
Female over 65++
Male (any age)+
Female 50–64+
Female over 65+
Male 18–49+
Male over 65−
Male over 65− Male 18–49−
Ethnicity (fitted
as random
effect)
Pakistani, other and
unknown ethnicity−
Pakistani and other
ethnicity−
Pakistani, other and
unknown ethnicity−
Pakistani and other ethnicity+
Morbidity and
health
behaviour
Mental health problem+ Mental health
problem+
Definitive diagnosis+ Definitive diagnosis+ Definitive diagnosis+
Clinical presentation
without definitive
diagnosis−
Clinical presentation
without definitive
diagnosis+
Overweight or obese
−
Underweight+++
Increasing
polypharmacy+++
Increasing
polypharmacy+++
Increasing
polypharmacy+++
Polypharmacy−
Consulting
behaviour
7–12 consultations per
annum−
13 or over consultations
per annum+
13 or over
consultations per
annum+
7–12 consultations per
annum+
13 or over consultations
per annum+++
Increasing missed
appointments+
Increasing missed
appointments+
Referrals Diagnostic−
Medicine−
MSK+
Neurology+
Specialist pain
management+++
Neurology+
Specialist pain
management+++
Medicine+
MSK+
Neurology+
Specialist pain
management+++
Surgery+
Neurology−
Specialist pain management−
Practice IMD Higher IMD+
IMD, Index of Multiple Deprivation; MSK, musculoskeletal
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